The Cancer Drugs Fund in Practice and Under the New Framework
- 3 April 2019
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 37 (7) , 953-962
Abstract
The Cancer Drugs Fund (CDF) was established in 2010 to improve access to treatments not routinely available. Having widely overspent, stricter budgeting rules were introduced in 2016. The CDF can now only include treatments with potential to be cost effective once sufficient data are collected.Keywords
This publication has 11 references indexed in Scilit:
- Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics, 2018
- The mapping of cancer incidence and mortality trends in the UK from 1980–2013 reveals a potential for overdiagnosisScientific Reports, 2018
- EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and UncertaintiesApplied Health Economics and Health Policy, 2018
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13BMJ, 2017
- How Much Longer Will We Put Up With $100,000 Cancer Drugs?Cell, 2017
- Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate EndpointsJAMA Internal Medicine, 2017
- Cancer Drugs Fund requires further reformBMJ, 2016
- Cancer Drugs Fund 2.0: A Missed Opportunity?PharmacoEconomics, 2016
- Overall Survival Should Be the Primary Endpoint in Clinical Trials for Advanced Non-Small-Cell Lung CancerCurrent Oncology, 2013
- Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry dataThe Lancet, 2011